GNS561, A NEW ORAL CLINICAL-STAGE SMALL MOLECULE COMBINED WITH ANTI-PD1 SHOWED REMARKABLE ANTI-TUMOR EFFECTS IN A TRANSGENIC IMMUNOCOMPETENT HEPATOCELLULAR CARCINOMA MOUSE MODEL (ASV-B) - Aix-Marseille Université Access content directly
Conference Papers Year : 2019
No file

Dates and versions

hal-02466433 , version 1 (04-02-2020)

Identifiers

  • HAL Id : hal-02466433 , version 1

Cite

Rachid, Madani, Tijeras-Raballand, Annemilai, Cindy Serdjebi, Sonia Brun, Christelle Ansaldi, et al.. GNS561, A NEW ORAL CLINICAL-STAGE SMALL MOLECULE COMBINED WITH ANTI-PD1 SHOWED REMARKABLE ANTI-TUMOR EFFECTS IN A TRANSGENIC IMMUNOCOMPETENT HEPATOCELLULAR CARCINOMA MOUSE MODEL (ASV-B). Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Nov 2019, Boston, MA, United States. pp.1189A. ⟨hal-02466433⟩
71 View
0 Download

Share

Gmail Facebook X LinkedIn More